KYBELLA™ is the first and only approved injectable drug for contouring moderate to severe submental fullness, a condition that is commonly referred to as a double chin.
KYBELLA is a non-human and non-animal formulation of deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, KYBELLA causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
KYBELLA (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat (double chin) in adults.
About Submental Fullness
Submental fullness is a common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance leading to an older and heavier look. Submental fullness can affect adults – both women and men – of all ages, weight and gender. Influenced by multiple factors including aging and genetics, submental fullness is often resistant to diet and exercise. According to a survey by the American Society for Dermatologic Surgery (ASDS), nearly as many consumers (68 percent) are bothered by submental fullness as by lines and wrinkles around the eyes (71 percent).
A Cooper Physician You Can Trust for KYBELLA Treatments
KYBELLA should only be administered by a trained health care professional. Only physicians who have participated in a training program will be able to purchase KYBELLA and treat patients.
Naomi Lawrence, MD, Head of the Division of Dermatology, Section of Procedural Dermatology, is the only Cooper physician, and the first physician in the southern New Jersey region, to be trained to administer KYBELLA to patients. Dr. Lawrence is board certified in dermatopathology and dermatology and is a member of the American Society for Dermatologic Surgery.
KYBELLA is administered by injections into the fat under the chin, tailored to the treatment goals of the patient and their physician. In clinical trials, many patients experienced visible results in two to fourtreatments, though up to six treatments may be administered.
Seventy-nine percent of KYBELLA-treated patients reported satisfaction with their appearance in association with their face and chin. Patients also reported improvement in the visual and emotional impact of submental fat when asked how happy, bothered, self-conscious, embarrassed, old and overweight they felt following treatment in relation to the decrease in the amount of their submental fat.
The most common adverse reactions were associated with the injection site and included swelling, bruising, pain, numbness, and the formation of areas of hardness in the treatment area.